Bace1 inhibitors

A compound of formula I,

• A is a heteoayl group,
• A is a heteroaryl group,
• B is a heteroaryl group,
• R1 is selected from the group consisting of
• i) C1-6-alkyl and
• ii) halogen-C1-6-alkyl;
• R2 is selected from the group consisting of
• i) C1-6-alkyl, and
• ii) halogen-C1-6-alkyl;
• or R1 and R2 form together with the C-atom they are attached to, a C3-6-cycloalkyl-, wherein the C3-6-cycloalkyl- is optionally substituted by one or more substituents selected from the group consisting of halogen and hydroxyl;
• R3 is selected from the group consisting of
• i) hydrogen,
• ii) C3-6-cycloalkyl,
• iii) halogen-C1-6-alkyl, and
• iv) C1-6-alkyl;
• R4 is selected from the group consisting of
• i) hydrogen, and
• ii) C1-6-alkyl;
• R5 is selected from the group consisting of
• i) C1-6-alkyl, and
• ii) halogen-C1-6-alkyl;
• R6 is halogen;
• R7 is selected from the group consisting of
• i) amino,
• ii) cyano,
• iii) hydrogen,
• iv) OH,
• v) halogen,
• vi) C1-6-alkyl,
• vii) C1-6-alkyl-C3-6-cycloalkyl,
• viii) halogen-C1-6-alkyl,
• ix) C1-6-alkoxy-C1-6-alkyl,
• x) C2-6-alkynyl,
• xi) C2-6-alkynyl-C1-6-alkyl,
• xii) C2-6-alkynyl-C1-6-alkoxy
• xiii) C1-6-alkoxy, and
• xiv) halogen-C1-6-alkoxy;
• or pharmaceutically acceptable salts thereof.